Megakaryon Corporation
- Medical Engineering & Biotechnology
Corporate Number｜2010401095710
In 1900, the Austrian pathologist Karl Landsteiner discovered the existence of blood groups and made transfusion medicine possible. Since then, transfusion has spread widely as one of the most basic medical treatments. While methods for blood preservation are advancing, transfusion requires blood and relies on the donations currently.
Now, more than 100 years later, Prof. Nakauchi at the University of Tokyo and Prof. Eto at Kyoto University with their team members have succeeded in developing techniques to produce platelets from iPS cells. We are establishing the techniques to produce a stable supply of safe and low-cost platelet products without relying on blood donations. This technological innovation can be considered a second revolution in transfusion medicine, one that the medical professions are eager to witness for more than a century.
Megakaryon Corporation was founded to promote the application of these techniques to clinical use. In cooperation with domestic and foreign academic research institutions and companies, Megakaryon will establish techniques to manufacture safe and low-cost platelet products constantly without relying on blood donations, achieve a second revolution in transfusion medicine, and contribute to the evolution of medical infrastructure all over the world.
